Literature DB >> 21102647

Postmenopausal hormone therapy: risks versus benefits reassessed.

James A Simon1.   

Abstract

Mesh：

Year:  2010        PMID： 21102647     DOI： 10.1038/nrendo.2010.191

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Estrogen replacement therapy: determinants of persistence with treatment.

Authors:  D Pilon; A M Castilloux; J LeLorier
Journal:  Obstet Gynecol       Date:  2001-01       Impact factor: 7.661

2.  Caring less, doing more: the role of therapeutic detachment with volatile and unmotivated clients.

Authors:  Virginia A Galloway; Stanley L Brodsky
Journal:  Am J Psychother       Date:  2003

Review 3.  The estrogen paradox.

Authors:  Richard J Santen; D Craig Allred
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-05-22

4.  Postmenopausal estrogen therapy: which route to take?

Authors:  James A Simon
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

5.  The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.

Authors:  James A Simon; Gerard G Nahum; Harold Stanislaw; Tatiana Gaines
Journal:  Maturitas       Date:  2010-05-14       Impact factor: 4.342

6.  Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Authors:  Elizabeth Barrett-Connor; Lori Mosca; Peter Collins; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Michelle A McNabb; Nanette K Wenger
Journal:  N Engl J Med       Date:  2006-07-13       Impact factor: 91.245

Review 7.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

Review 8.  Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart.

Authors:  Howard N Hodis
Journal:  Cleve Clin J Med       Date:  2008-05       Impact factor: 2.321

9.  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

Authors:  Matthew J Ellis; Feng Gao; Farrokh Dehdashti; Donna B Jeffe; P Kelly Marcom; Lisa A Carey; Maura N Dickler; Paula Silverman; Gini F Fleming; Aruna Kommareddy; S Jamalabadi-Majidi; Robert Crowder; Barry A Siegel
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  10 in total
  1 in total

1.  A meta-analysis of reference values of leptin concentration in healthy postmenopausal women.

Authors:  Xi Zhou; YanLan Chai; Ke Chen; YunYi Yang; Zi Liu
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.